Back to Stakeholders

Hospitals Independent Academic Research Groups

Mclean Hospital

United States

4 Trials

Harvard Medical School-affiliated psychiatric hospital and one of the leading mental health research institutions in the United States. Operates a dedicated Ketamine Service for treatment-resistant depression and is actively expanding into psilocybin research for depression, bipolar disorder, and other psychiatric conditions.

Quick Facts

Type: Other
HQ: United States
Website: Visit

Sponsored Trials

2

Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression

Start Date: August 17, 2020
Compounds: Ketamine

Unknown statusNA

Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder

Start Date: June 4, 2019
Compounds: Ketamine

Collaborated Trials

2

Enrolling by invitationIV

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan (REaKT-SD)

Start Date: October 1, 2023
Compounds: Ketamine, Placebo

MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer

Start Date: January 12, 2007
Compounds: MDMA